Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Zhu, WangYu ^a   Zhou, KaiYu ^a   Zha, Yao ^a   Chen, DongDong ^a   He, JianYing ^a   Ma, HaiJie ^a   Liu, XiaoGuang ^a   Le, HanBo ^a   Zhang, YongKui ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 126; MICRORNA 182; MICRORNA 183; MICRORNA 210; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PNEUMONIA; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; STOMACH CANCER; UPREGULATION; AREA UNDER THE CURVE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84964687235     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153046     Document Type: Article

References (47)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29. doi: 10.3322/caac.21254 PMID: 25559415
2. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13, 010 resected lung cancers. J Thorac Oncol. 2008; 3:46-52. doi: 10.1097/JTO.0b013e31815e8577 PMID: 18166840
3. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013; 369:920-31. doi: 10.1056/NEJMoa1208962 PMID: 24004119
4. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014; 20:4613-24. doi: 10.1158/1078-0432CCR-13-3063 PMID: 25013125
5. Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer. 2014; 110:2054-62. doi: 10.1038/bjc.2014.104 PMID: 24642624
6. Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93, and miR-429as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 2014; 9:e87780. doi: 10.1371/journal.pone.0087780 PMID: 24523873
7. Zhu WY, Luo B, An JY, He JY, Chen DD, Xu LY, et al. Differential expression of miR-125a-5pandlet-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest. 2014; 32:394-401. doi: 10.3109/07357907.2014.922569 PMID: 24945821
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105:10513-8. doi: 10.1073/pnas.0804549105 PMID: 18663219
9. Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013; 81:388-96. doi: 10.1016/j.lungcan.2013.05.007 PMID: 23756108
10. Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013; 133:645-52. doi: 10.1002/ijc.28054 PMID: 23354517
11. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013; 22:540-8. doi: 10.1097/CEJ.0b013e32835f3be9 PMID: 23462458
12. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and post-operative lung carcinoma patients. Med Oncol. 2012; 29:3190-7. doi: 10.1007/s12032-012-0303-z PMID: 22782668
13. Zhu W, Liu X, He J, Chen D, Hunag Y and Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011; 11:393. doi: 10.1186/1471-2407-11-393 PMID: 21920043
14. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification often serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012; 130:1620-8. doi: 10.1002/ijc.26177 PMID: 21557218
15. Wang P, Yang D, Zhang H, Wei X, Ma T, Cheng Z, et al. Early detection of lung cancer in serum by a panel of microRNA biomarkers. Clin Lung Cancer. 2015; 16:313-9.e1. doi: 10.1016/j.cllc.2014.12.006 PMID: 25639977
16. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014; 12:1738-61. PMID: 25505215
17. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl ComprCanc Netw. 2013; 11:531-46. PMID: 23667204
18. Zheng G WH, Zhang X, Yang Y, Wang L, Du L, Li W, Li J, Qu A, Liu Y, Wang C. Identification and validation of reference genes for qPCR detection of serum microRNAs in colorectal adenocarcinoma patients. PloS one 2013; 8.
19. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18:997-1006. doi: 10.1038/cr.2008.282 PMID: 18766170
20. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-8. PMID: 11846609
21. DeLong ER, DeLong DM and Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837-45. PMID: 3203132
22. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011; 91:579-87. doi: 10.1038/labinvest.2010.194 PMID: 21116241
23. Kroh EM, Parkin RK, Mitchell PS and Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50:298-301. doi: 10.1016/j.ymeth.2010.01.032 PMID: 20146939
24. Hu J, Wang Z, Liao BY, Yu L, Gao X, Lu S, et al. Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer. 2014; 135:1187-94. doi: 10.1002/ijc.28757 PMID: 24488924
25. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED and Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012; 130:1378-86. doi: 10.1002/ijc.26153 PMID: 21544802
26. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-66. PMID: 17060945
27. Sarver AL, Li L and Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010; 70:9570-80. doi: 10.1158/0008-5472.CAN-10-2074 PMID: 21118966
28. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, et al. Pleiotropic effects of miR-183-96-182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012; 123:539-52. doi: 10.1007/s00401-012-0969-5 PMID: 22402744
29. Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, et al. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene. 2013; 527:26-32. doi: 10.1016/j.gene.2013.06.006 PMID: 23791657
30. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011; 4:575-86. PMID: 21904633
31. Abd-El-Fattah AA, Sadik NA, Shaker OG and Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013; 67:875-84. doi: 10.1007/s12013-013-9575-y PMID: 23559272
32. Lin Q, Mao W, Shu Y, Lin F, Liu S, Shen H, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol. 2012; 138:85-93. doi: 10.1007/s00432-011-1068-z PMID: 22009180
33. Jusufovic E, Rijavec M, Keser D, Korosec P, Sodja E, Iljazovic E, et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One. 2012; 7:e45577. doi: 10.1371/journal.pone.0045577 PMID: 23029111
34. Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor - A predicts poor survival. Cancer. 2011; 117:3193-200. doi: 10.1002/cncr.25907 PMID: 21264844
35. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373:607-12. doi: 10.1016/j.bbrc.2008.06.090 PMID: 18602365
36. Huang X, Le QT and Giaccia AJ. MiR-210-micromanager of the hypoxia pathway. Trends Mol Med. 2010; 16:230-7. doi: 10.1016/j.molmed.2010.03.004 PMID: 20434954
37. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014; 83:272-8. doi: 10.1016/j.lungcan.2013.11.005 PMID: 24305009
38. Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med. 2012; 35:E271. PMID: 23043708
39. Li Q, Long A, Jiang L, Cai L, Xie LI, Gu J, et al. Quantification of preeclampsia-related microRNAs in maternal serum. Biomed Rep. 2015; 3:792-6. PMID: 26623017
40. Chen L, Chu F, Cao Y, Shao J and Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour Biol. 2015; 36:7439-47. doi: 10.1007/s13277-015-3430-2 PMID: 25903466
41. Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett. 2013; 6:1681-6. PMID: 24260062
42. Wang Y, Liang Z, Gao Y, Zhai D, Rao Q, Shi W, et al. Factors influencing circulating MicroRNA level in the studies of hepatocellular carcinoma biomarker. Neoplasma. 2015; 62:798-804. doi: 10.4149/neo 2015 096 PMID: 26278140
43. Zhang C, Wang Q, Xi X, Jiao J, Xu W, Huang J, et al. High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients. Int J Clin Exp Pathol. 2015; 8:655-9. PMID: 25755759
44. Tang X, Chen L, Yan X, Li Y, Xiong Y and Zhou X. Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia. Med Sci Monit. 2015; 21:3427-33. PMID: 26549593
45. Fedorko M, Stanik M, Iliev R, Redova-Lojova M, Machackova T, Svoboda M, et al. Combination of miR-378 and miR-210 serum levels enables sensitive detection of renal cell carcinoma. Int J Mol Sci. 2015; 16:23382-9. doi: 10.3390/ijms161023382 PMID: 26426010
46. Yang Y, Qu A, Liu J, Wang R, Liu Y, Li G, et al. Serum miR-210 contributes to tumor detection, stage prediction and dynamic surveillance in patients with bladder cancer. PLoS One. 2015; 10:e0135168. doi: 10.1371/journal.pone.0135168 PMID: 26252880
47. Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012; 45:575-81. doi: 10.1016/j.clinbiochem.2012.02.009 PMID: 22374169